{
    "ticker": "ALCY",
    "name": "Alcyone Therapeutics, Inc.",
    "description": "Alcyone Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare and complex neurological disorders. Founded in 2012, the company is dedicated to addressing unmet medical needs by leveraging advanced delivery technologies and proprietary formulations. Alcyone's lead product candidate, AIC-100, is designed to enhance the bioavailability of therapeutic agents through targeted delivery to the central nervous system, aiming to improve outcomes for patients with conditions such as Alzheimer's disease and multiple sclerosis. The company's commitment to research and development is bolstered by collaborations with leading academic institutions and research organizations. Alcyone is also working on expanding its pipeline, exploring novel therapeutic approaches to treat various neurological and psychiatric disorders. With a patient-centric approach, Alcyone aims to bring transformative solutions to the market, improving the quality of life for patients and their families.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2012",
    "website": "https://www.alcyonetherapeutics.com",
    "ceo": "Dr. Michael P. F. Binz",
    "social_media": {
        "twitter": "https://twitter.com/AlcyoneThera",
        "linkedin": "https://www.linkedin.com/company/alcyone-therapeutics/"
    },
    "investor_relations": "https://www.alcyonetherapeutics.com/investor-relations",
    "key_executives": [
        {
            "name": "Dr. Michael P. F. Binz",
            "position": "CEO"
        },
        {
            "name": "Mr. John Doe",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "AIC-100"
            ]
        }
    ],
    "seo": {
        "meta_title": "Alcyone Therapeutics, Inc. | Innovative Neurological Therapies",
        "meta_description": "Explore Alcyone Therapeutics, Inc., a leader in biotechnology developing targeted therapies for neurological disorders. Learn about their innovative products and research.",
        "keywords": [
            "Alcyone Therapeutics",
            "biotechnology",
            "neurological disorders",
            "AIC-100",
            "Alzheimer's disease",
            "multiple sclerosis"
        ]
    },
    "faq": [
        {
            "question": "What does Alcyone Therapeutics focus on?",
            "answer": "Alcyone Therapeutics focuses on developing innovative therapies for rare and complex neurological disorders."
        },
        {
            "question": "Who is the CEO of Alcyone Therapeutics?",
            "answer": "Dr. Michael P. F. Binz is the CEO of Alcyone Therapeutics, Inc."
        },
        {
            "question": "Where is Alcyone Therapeutics headquartered?",
            "answer": "Alcyone Therapeutics is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is Alcyone's lead product candidate?",
            "answer": "Alcyone's lead product candidate is AIC-100, aimed at improving bioavailability for neurological therapies."
        },
        {
            "question": "When was Alcyone Therapeutics founded?",
            "answer": "Alcyone Therapeutics was founded in 2012."
        }
    ],
    "competitors": [
        "AVXL",
        "SGMO",
        "VRTX",
        "BIIB"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "BMY"
    ]
}